PT86651A - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
PT86651A
PT86651A PT86651A PT8665188A PT86651A PT 86651 A PT86651 A PT 86651A PT 86651 A PT86651 A PT 86651A PT 8665188 A PT8665188 A PT 8665188A PT 86651 A PT86651 A PT 86651A
Authority
PT
Portugal
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
PT86651A
Other languages
English (en)
Other versions
PT86651B (pt
Inventor
William John Coates
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878702301A external-priority patent/GB8702301D0/en
Priority claimed from GB878702300A external-priority patent/GB8702300D0/en
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of PT86651A publication Critical patent/PT86651A/pt
Publication of PT86651B publication Critical patent/PT86651B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT86651A 1987-02-02 1988-01-28 Processo de preparacao de derivados da purinona PT86651B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878702301A GB8702301D0 (en) 1987-02-02 1987-02-02 Chemical compounds
GB878702300A GB8702300D0 (en) 1987-02-02 1987-02-02 Chemical compounds

Publications (2)

Publication Number Publication Date
PT86651A true PT86651A (pt) 1988-02-01
PT86651B PT86651B (pt) 1992-02-28

Family

ID=26291861

Family Applications (1)

Application Number Title Priority Date Filing Date
PT86651A PT86651B (pt) 1987-02-02 1988-01-28 Processo de preparacao de derivados da purinona

Country Status (10)

Country Link
US (1) US4885301A (pt)
EP (1) EP0293063B1 (pt)
AU (1) AU599452B2 (pt)
CA (1) CA1303037C (pt)
DE (1) DE3869205D1 (pt)
DK (1) DK40788A (pt)
ES (1) ES2033423T3 (pt)
GR (1) GR3003956T3 (pt)
IE (1) IE880213L (pt)
PT (1) PT86651B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809481D0 (en) * 1988-04-21 1988-05-25 Smith Kline French Lab Chemical compounds
GB8814352D0 (en) * 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
FI951367A (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501480A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
UA46166C2 (uk) * 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
EP1120120A4 (en) * 1998-10-05 2009-04-29 Eisai R&D Man Co Ltd TABLETS DISSOLVING DIRECTLY IN MOUTH
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
CA2449163C (en) * 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
MXPA04009997A (es) * 2002-04-12 2004-12-13 Celgene Corp Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas.
WO2003086373A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
AU2006299232A1 (en) * 2005-09-29 2007-04-12 Bayer Schering Pharma Aktiengesellschaft PDE inhibitors and combinations thereof for the treatment of urological disorders
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
WO2009120296A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3437661A (en) * 1964-01-18 1969-04-08 Kyowa Hakko Kogyo Kk Process of producing purine derivatives
DE1545574A1 (de) * 1964-12-14 1969-07-31 Ajinomoto Kk Verfahren zur Herstellung von Hypoxanthin und dessen Derivaten
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US3819631A (en) * 1970-12-15 1974-06-25 May & Baker Ltd Azapurinones
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
DE3131365A1 (de) * 1981-08-07 1983-02-24 Henkel KGaA, 4000 Düsseldorf Neue diglycidyl-substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung in arzneimittelzubereitungen mit cytostatischer wirksamkeit
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators

Also Published As

Publication number Publication date
IE880213L (en) 1988-08-02
DK40788A (da) 1988-08-03
ES2033423T3 (es) 1993-03-16
AU599452B2 (en) 1990-07-19
EP0293063B1 (en) 1992-03-18
AU1095688A (en) 1988-08-04
DE3869205D1 (de) 1992-04-23
EP0293063A1 (en) 1988-11-30
CA1303037C (en) 1992-06-09
GR3003956T3 (pt) 1993-03-16
DK40788D0 (da) 1988-01-27
PT86651B (pt) 1992-02-28
US4885301A (en) 1989-12-05

Similar Documents

Publication Publication Date Title
DK40788D0 (da) Kemiske forbindelser
NO172440C (no) Kjemisk forbindelse
DK85993D0 (da) 2-anilino-4-formyl-pyrimidinforbindelser
BA98296A (bs) Piperazinil-heterociklicna jedinjenja
DK90788D0 (da) Kemiske forbindelser
DK666188D0 (da) Kemiske formuleringer
DK583684D0 (da) Kemiske forbindelser
DK594687D0 (da) Pyrrolidinylthioforbindelser
DK406586D0 (da) Kemiske forbindelser
DK356686A (da) Kemiske forbindelser
DK96986A (da) Kemiske forbindelser
DK593088D0 (da) Organiske forbindelser
DK301885D0 (da) Kemiske forbindelser
NO880809D0 (no) Antihyperkloresterolemiske tetrazolforbindelser.
PT84187A (pt) Novel compounds
DK483689D0 (da) Kemiske forbindelser
DK109886D0 (da) Kemiske forbindelser
PT86766A (pt) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
IT1221792B (it) Composti metossimetilici
DK346186D0 (da) Kemiske forbindelser
ATE93512T1 (de) Oximino-aether-verbindungen.
DK375287A (da) Fungicid indeholdende substituerede thienylaminer
DK519188D0 (da) Kemisk forbindelse
DE3878192D1 (de) N-phenyltetrahydrophthalimidverbindungen.
DK182587A (da) 3-diphenyl-substituerede octahydroindolizinforbindelser

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19910808

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19940228